#Allergy, Antibody, Biotech, Clinical Trials, Drug Development, Funding, Mabylon, Roche
2 articles with this tag
Funding Round
Mabylon Raises €31.8M to Advance Allergy Antibody Pipeline
Zurich-based Mabylon , a Swiss biotech scale-up, secured €31.8 million in new funding. This Mabylon funding round will advance its lead peanut allergy program.
7 months ago
Funding Round
Mabylon Raises €31.8M to Advance Allergy Antibody Pipeline
Mabylon, a Swiss biotech, secured €31.8 million in new funding. This investment will advance its lead peanut allergy program and early-stage pipeline. The funding came from existing private investors, including former Roche management and board members.
7 months ago